Medtronic Launches Aristotle Mini for Neurovascular Access

Medtronic has launched Aristotle Mini, a low-profile neurovascular guidewire designed to access small, distant brain vessels and help stop internal bleeding, paired with the company’s Onyx liquid embolic platform for chronic subdural hematoma (cSDH) treatment. Reported in early November 2026, the product is the first commercial pull-through from Medtronic’s $550m Scientia Vascular acquisition and arrives with an FDA clearance from August 2026 and a phased commercial launch now underway.

The Aristotle Mini guidewire combines nitinol and stainless steel construction and is compatible with microcatheters carrying a 0.013-inch inner diameter. Medtronic expects the device to support procedures for both cSDH and hard-to-navigate arteriovenous malformations and fistulas, extending the company’s neurovascular access toolkit into more complex anatomy. Linnea Burman, President of Medtronic’s Neurovascular Business, framed the launch around the growing cSDH burden, which Medtronic expects to become one of the most common neurosurgical conditions by 2030. Dr Adam Arthur, Chief Medical Officer of Medtronic’s Neurovascular Business, positioned the lower-profile access option around clinical flexibility given the significant patient-to-patient anatomical variation in middle meningeal artery (MMA) embolization procedures.

Onyx, the paired liquid embolic polymer platform, received expanded FDA approval late last year for cSDH treatment by blocking the middle meningeal artery, forming a solid mass after microcatheter delivery. The combined Aristotle Mini-Onyx workflow strengthens Medtronic’s cSDH commercial positioning as the condition’s clinical and commercial profile grows alongside ageing demographics and anticoagulant use. The Scientia Vascular acquisition, which closed in June 2026, delivered Medtronic a differentiated laser-cut polymer-coated micro guidewire platform targeting the approximately $100m neuro guidewire market. The Aristotle Mini commercial launch marks the first visible integration milestone from that deal, with further guidewire and catheter product line extensions expected across Medtronic’s broader neurovascular franchise through 2027. The phased launch approach reflects typical neurovascular device rollout patterns, prioritising high-volume stroke and MMA embolization centres before broader US penetration.

The commercial signal is a maturing neurovascular device category where chronic subdural hematoma is emerging as a substantial new growth driver alongside established ischaemic stroke and aneurysm indications, with device-liquid embolic combination workflows reshaping procedural economics. Scientia Vascular integration milestones anchor Medtronic’s neurovascular commercial trajectory. Expect sustained neurovascular device launch activity and continued focus on cSDH procedural adoption through 2027 and 2028.

For the latest updates and in-depth insights into the world of Medical Devices, including breakthrough treatments, industry trends, and regulatory news, contact  Albert Baines today!